Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.53 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.51 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836775 | 0.98 | LOXL2 (0.61) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| SCHEMBL134170 | 0.98 | LOXL2 (0.61) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| O-Xylene SCHEMBL27792225 | 0.90 | LMNA (0.57) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| Hydrochloric Acid SCHEMBL6233341 | 0.90 | CA12 (0.60) | LOXL2TSHRALDH1A1MAPTRAB9A | |
| Toluene SCHEMBL27792204 | 0.88 | TSHR (0.56) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| SCHEMBL29441704 | 0.87 | CA12 (0.61) | LOXL2TSHRALDH1A1MAPTRAB9A | |
| SCHEMBL2875365 | 0.87 | CA12 (0.61) | LOXL2TSHRALDH1A1MAPTRAB9A | |
| SCHEMBL7531618 | 0.87 | LOXL2 (0.50) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| SCHEMBL7908137 | 0.86 | PBRM1 (0.66) | LOXL2TSHRALDH1A1PBRM1KDM4E | |
| SCHEMBL8367495 | 0.84 | L3MBTL1 (0.56) | LOXL2TSHRALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115057859-B | Compound with antitumor and antifungal activity and application thereof | 中国人民解放军海军军医大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-115057859-A | Compound with antitumor and antifungal activities and application thereof | 中国人民解放军海军军医大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-108101845-B | Preparation method of eltrombopag | 苏州科伦药物研究有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| CN-105008354-A | Protein kinase inhibitors | ORIBASE PHARMA | 2015-10-28 | — | — | CN | disclosed |
| CN-102584940-B | Peptidic compounds | UNIV WOLLONGONG | 2014-12-31 | — | — | CN | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
| EP-0081838-B1 | CYCLOHEXYL AND PHENYL SUBSTITUTED ENKEPHALINS | G.D. Searle & Co. (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4407746-A | Cyclohexyl and phenyl substituted enkephalins | G. D. SEARLE & CO. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0081838-A1 | Cyclohexyl and phenyl substituted enkephalins | G.D. Searle & Co. (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | GLA 3735/4885GAA 1820/4885ADRB2 3067/4885 |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | GLA 826/4885GAA 477/4885ADRB2 85/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | GLA 2852/4885GAA 1534/4885ADRB2 4654/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | GLA 826/4885GAA 477/4885ADRB2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.